Assess whether pediatric studies are necessary or waivable (347930)

Situation

After a site-change that invalidates stability claims, complete-response-letter deficiency list is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Pediatric studies are necessary versus Waivable on this CMC and Development Pathways file.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize Pediatric studies are necessary now; complete-response-letter deficiency list already has the discriminator after a site-change that invalidates stability claims.
• Keep Waivable in force until complete-response-letter deficiency list is completed after a site-change that invalidates stability claims for labeling negotiator.
• Treat complete-response-letter deficiency list as Pediatric studies are necessary because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page pediatric studies are necessary turns on in complete-response-letter deficiency list.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether complete-response-letter deficiency list supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.